PhD, BSc Hons
Senior Research Fellow
- About
-
- Telephone Number
- +44 (0)1224 274238
- School/Department
- School of Natural and Computing Sciences
Qualifications
- PhD Chemistry2002 - University of Aberdeen
- BSc Hons Chemistry1998 - University of Aberdeen
External Memberships
- Head of DMPK / Analytical Chemistry for TauRx Therapeutics
- Cofounder of the North East Analytical Research (NEAR) Symposium
Latest Publications
Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
International Journal of Molecular Sciences, vol. 24, no. 13, 10810Contributions to Journals: ArticlesNovel Method of Analysis for the Determination of Residual Formaldehyde by High-Performance Liquid Chromatography
International journal of analytical chemistry, vol. 2022, 9171836Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1155/2022/9171836
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/30d761b6-cd1d-41b8-9a27-332deb2c1c20/download
- [ONLINE] View publication in Scopus
HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
Biomedicines, vol. 10, no. 4, 867Contributions to Journals: ArticlesConcentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Journal of Alzheimer's Disease, vol. 75, no. 2, pp. 501-519Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/JAD-191173
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/53b6ee0c-d5be-45c3-90a0-1afea8f620c4/download
- [ONLINE] View publication in Scopus
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease
Journal of Alzheimer's Disease, vol. 72, no. 3, pp. 931-946Contributions to Journals: Articles
- Research
-
Research Overview
My focus is on the analytical pathways involved in pharmaceutical drug development.
- This starts early during R and D looking at physical chemical testing of novel compounds and early analytical development to determine material purity and its impurities.
- As the candidates progress further, bioanalytical methods, initial metabolism and material characterisation are developed.
- Once into non clinical and clinical development validation according to ICH Q3 is required for material assays and ICH M7 for bioanalytical methods
Current Research
The development and use of new analytical methods in the study of small organic molecules undergoing clinical evaluation.
The development and use of bioanalytical methods used in clinical and non clinical studies
DMPK studies supporting novel pharmaceutical development
Past Research
The synthesis and study of novel organic compounds for use as potential drug candidates and excipients.
The study of the physical properties of novel oligosaccharides
Knowledge Exchange
Speaker at NEAR Symposium 2024 in Aberdeen
Speaker at REID bioanalytical Forum 2019, Cambridge
Speaker at INFORM 2018 in Copenhagen
- Publications
-
Page 2 of 4 Results 11 to 20 of 35
A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
Frontiers in Molecular Neuroscience, vol. 10, 447Contributions to Journals: ArticlesStructural studies of (E)-2-(benzylidene)-1- tetralone derivatives: Crystal structures and Hirshfeld surface analysis
Zeitschrift fur Kristallographie - Crystalline Materials, vol. 232, no. 10, pp. 697-718Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1515/zkri-2017-2048
- [ONLINE] View publication in Scopus
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development
Frontiers in Immunology, vol. 8, 1361Contributions to Journals: ArticlesCrystal structures of four 1-(aryl)-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
Journal of Molecular Structure, vol. 1128, pp. 579-589Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.molstruc.2016.09.021
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1124/jpet.114.219352
Tautomers and polymorphs of pyrazolinone derivatives, generated from reactions of arylhydrazines, ArNHNH2, with 1,3-dicarbonyl compounds
Zeitschrift fur Kristallographie, vol. 228, no. 2, pp. 77-91Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1524/zkri.2013.1575
- [ONLINE] View publication in Scopus
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Patents: PatentsVariation in supramolecular arrangements of hydrazones, o-H2NC6H4CMe=NNHC6H4X (X = H, o-, m- and p-NO2), derived from o-aminoacetophenone and phenylhydrazines
Journal of Molecular Structure, vol. 1020, pp. 16-22Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.molstruc.2012.04.023
1,3-Diphenyl-4,5-dihydro-1H-pyrazol-5-one
Acta Crystallographica Section E: Structure Reports Online, vol. E68, pp. o1016-o1017Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1107/S1600536812009567
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Patents: Patents